Custom Search

News

Wednesday 01 December 2004

Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis.

By: Lian EC, Tzakis AG, Andrews D.

Am J Hematol 2004 Dec;77(4):363-5

A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjogren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375-500 mg/m2 rituximab. 2004 Wiley-Liss, Inc.

Use of this site is subject to the following terms of use